Glucotrack, Inc. Encourages Shareholders to Vote

Core Points - Glucotrack, Inc. will reconvene a Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund [1][2] - The company encourages shareholders to vote as soon as possible to comply with NASDAQ Listing Rule 5635(d), which allows the issuance of more than 20% of the company's outstanding Common Stock through a $20 million Purchase Agreement [2] - Shareholders of record as of September 23, 2025, are eligible to vote, and the company provides multiple voting methods including telephone and online options [3][4] Voting Recommendations - The Board of Directors unanimously recommends that shareholders vote "FOR" all proposals, emphasizing the importance of every vote [5] - Shareholders are encouraged to ensure that all their accounts are voted to represent their shares fully [4] Additional Information - Detailed information regarding the proposals can be found in the definitive proxy statement filed with the SEC on October 3, 2025 [6] - Shareholders needing assistance with voting can contact the company's proxy solicitation firm, Sodali & Co. [7] Company Overview - Glucotrack, Inc. focuses on developing novel technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [8] - The company's continuous blood glucose monitoring (CBGM) system is designed for a sensor longevity of 3 years, with minimal calibration required [9]